|
|
|
|
Sciele Pharma, Inc. - Strategic Analysis Review - new market report published
Refer to a friend 2010-03-19 11:05:02 - Sciele Pharma, Inc.- Strategic Analysis Review - a new market research report on companiesandmarkets.com Sciele Pharma, Inc. - Strategic Analysis Review Summary The Sciele Pharma, Inc. - Strategic...
|
|
|
Purdue Pharma L.P. - Strategic Analysis Review - new market report published
Refer to a friend 2010-03-19 11:07:02 - Purdue Pharma L.P.- Strategic Analysis Review - a new market research report on companiesandmarkets.com Purdue Pharma L.P. - Strategic Analysis Review Summary The Purdue Pharma L.P. - Strategic...
|
|
|
Astellas Says Regulatory Waiting Period To Acquire OSI Pharma Expires - Update
(RTTNews) - Japanese pharmaceutial company Astellas Pharmaceuticals Inc.(ALPMY.PK: News ) announced Friday that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, to acquire OSI Pharmaceuticals Inc. ...
|
|
|
A.P. Pharma sinks; sector indices sluggish
Biotechnology Pharmaceuticals AP Pharma Inc Nyse Arca Pharmaceutical Story Quotes Comments Screener AlertEmail Print By Val Brickates Kennedy APPADRG BTK BOSTON (MarketWatch) -- A.P.Pharma /quotes/comstock/15*!appa/quotes/nls/appa ...
|
|
|
A.P. Pharma Receives FDA Complete Response Letter for APF530
- REDWOOD CITY, Calif.--(BUSINESS WIRE)-- A.P.Pharma, Inc. (Nasdaq: APPA), a specialty pharmaceutical company, today announced that it received a Complete Response Letter from the U.S. Food and Drug Administration (FDA or Agency) regarding...
|
|
|
A.P. Pharma Receives FDA Complete Response Letter for APF530
- REDWOOD CITY, Calif.--(BUSINESS WIRE)-- A.P.Pharma, Inc. (Nasdaq: APPA), a specialty pharmaceutical company, today announced that it received a Complete Response Letter from the U.S. Food and Drug Administration (FDA or Agency) regarding...
|
|
|
A.P. Pharma Receives FDA Complete Response Letter for APF530
- REDWOOD CITY, Calif.--(BUSINESS WIRE)-- A.P.Pharma, Inc. (Nasdaq: APPA), a specialty pharmaceutical company, today announced that it received a Complete Response Letter from the U.S. Food and Drug Administration (FDA or Agency) regarding...
|
|
|
A.P. Pharma Receives FDA Complete Response Letter for APF530
- REDWOOD CITY, Calif.--(BUSINESS WIRE)-- A.P.Pharma, Inc. (Nasdaq: APPA), a specialty pharmaceutical company, today announced that it received a Complete Response Letter from the U.S. Food and Drug Administration (FDA or Agency) regarding...
|
|
|
The Specialty Pharmaceutical Market Outlook: Key players, opportunities and future trends - new market report published
Refer to a friend 2010-03-19 19:09:03 - The Specialty Pharmaceutical Market Outlook: Key players, opportunities and future trends - a new market research report on companiesandmarkets.com The Specialty Pharmaceuticals Market Outlook reveals market...
|
|
|
Axcan Pharma Inc. - Strategic Analysis Review - new market report published
Axcan Pharma Inc.- Strategic Analysis Review Summary The Axcan Pharma Inc. - Strategic Analysis Review is an in-depth business and strategic analysis of Axcan Pharma Inc.. The report provides a comprehensive insight into the company,...
|
|
|
Purdue Pharma L.P. - Strategic Analysis Review
SummaryThe '' is an in-depth business and strategic analysis of 'Purdue Pharma L.P.'.The report provides a comprehensive insight into the company, including business structure and operations, executive biographies and key competitors. The hallmark of...
|
|
|
A.P. Pharma Receives FDA Complete Response Letter for APF530
Pharma, Inc.(Nasdaq:APPA), a specialty pharmaceutical company, today announced that it received a Complete Response Letter from the U.S. Food and Drug Administration (FDA or Agency) regarding its New Drug Application (NDA) for APF530 in the...
|
|
|
A.P. Pharma Receives FDA Complete Response Letter for APF530
REDWOOD CITY, Calif.--(BUSINESS WIRE)--A.P.Pharma, Inc. (Nasdaq: APPA), a specialty pharmaceutical company, today announced that it received a Complete Response Letter from the U.S. Food and Drug Administration (FDA or Agency) regarding its...
|
|
|
A.P. Pharma Receives FDA Complete Response Letter for APF530
Companies mentioned in this article: A.P.Pharma, Inc. REDWOOD CITY, Calif. -- (BUSINESS WIRE) -- A.P. Pharma, Inc. (Nasdaq:APPA), a specialty pharmaceutical company, today announced that it received a Complete Response Letter from...
|
|
|
A.P. Pharma Receives FDA Complete Response Letter for APF530
REDWOOD CITY, Calif.(BUSINESS WIRE) A.P.Pharma, Inc. (Nasdaq:APPA), a specialty pharmaceutical company, today announced that it received a Complete Response Letter from the U.S. Food and Drug Administration (FDA or Agency) regarding its New...
|
|
|
A.P. Pharma Receives FDA Complete Response Letter for APF530
(BUSINESS WIRE) -- A.P.Pharma, Inc. (Nasdaq:APPA), a specialty pharmaceutical company, today announced that it received a Complete Response Letter from the U.S. Food and Drug Administration (FDA or Agency) regarding its New Drug Application ...
|
|
|
A.P. Pharma Receives FDA Complete Response Letter for APF530
(BUSINESS WIRE) -- A.P.Pharma, Inc. (Nasdaq:APPA), a specialty pharmaceutical company, today announced that it received a Complete Response Letter from the U.S. Food and Drug Administration (FDA or Agency) regarding its New Drug Application ...
|
|
|
A.P. Pharma Receives FDA Complete Response Letter for APF530
BusinessWire - A.P.Pharma, Inc. (Nasdaq:APPA), a specialty pharmaceutical company, today announced that it received a Complete Response Letter from the U.S. Food and Drug Administration (FDA or Agency) regarding its New Drug Application (NDA)...
|
|
|
Sun Pharma Announces USFDA Approval for Generic Prometh Syrup
Source : Sun Pharmaceuticals Industries Ltd Sun Pharma Announces USFDA Approval for Generic Prometh Syrup Sun Pharmaceutical Industries Ltd.(Reuters: SUN.BO, Bloomberg: SUNP IN, NSE:SUNPHARMA, BSE: 524715) announced that the USFDA has...
|
|
|
The Specialty Pharmaceutical Market Outlook: Key players, opportunities and future trends - new market report
The Specialty Pharmaceuticals Market Outlook reveals market dynamics, leading players and key therapy areas of opportunity for specialty pharma companies.Market drivers include increasing reimbursement from national health bodies and governments,...
|
|
|
Astellas Announces Changes to Director Nominees for Election to OSI Pharmaceuticals' Board of Directors
See more news releases in: Health Care & Hospitals, Medical Pharmaceuticals, Pharmaceuticals, Personnel Announcements TOKYO, March 19 /PRNewswire/ -- Astellas Pharma Inc.(TSE: 4503) today notified OSI Pharmaceuticals Inc. ...
|
|
|
FDA Denies Approval For A. P. Pharma's Nausea Treatment
The Food and Drug Administration issued a complete response letter to A.Pharma Inc. (Nasdaq: APPA) denying approval for the company's chemotherapy induced nausea treatment APF530 sending the stock price plummeting 91 cents to $1.15. The Food and...
|
|
|
A.P. Pharma Receives FDA Complete Response Letter for APF530
REDWOOD CITY, Calif.Pharma, Inc. (Nasdaq:APPA), a specialty pharmaceutical company, today announced that it received a Complete Response Letter from the U.S. Food and Drug Administration (FDA or Agency) regarding its New Drug Application (NDA...
|
|
|
A.P. Pharma Receives FDA Complete Response Letter for APF530
- Company to host conference call at 9:00 a.m.ET on Friday, March 19, 2010 - REDWOOD CITY, Calif.--(BUSINESS WIRE)--A.P. Pharma, Inc. (Nasdaq:APPA - News), a specialty pharmaceutical company, today announced that it received a Complete...
|
|
|
A.P. Pharma Receives FDA Complete Response Letter for APF530
REDWOOD CITY, Calif.--(EON: Enhanced Online News)--A.P.Pharma, Inc. (Nasdaq:APPA), a specialty pharmaceutical company, today announced that it received a Complete Response Letter from the U.S. Food and Drug Administration (FDA or Agency)...
|
